• Radiation Oncology Journal
• /
• v.6 no.1
• /
• pp.1-11
• /
• 1988

Recovery from potentially lethal damage (PLDR) after irradiation was studied in plateau-phase culture of Vero cells in vitro. Unfed plateau-phase cells were irradiated with dose of 1 to 9Gy using Cs-137 irradiator. Cells then were incubated again and left in situ for 0, 1, 2, 3, 4, 5, 6, and 24 hours and then were trypsinized explanted, and subcultured in fresh RPMI-1640 media containing $0.33\%$ agar. Cell survival was measured by colony forming ability. An adequate number of heavily irradiated Vero cells were added as feeder cells to make the total cell number constant in every culture dish. As the postirradiation in situ incubation time increased, surviving fraction increased by PLDR. The rate of PLDR was so rapid that increased surviving fraction reached saturation level at 2 to 4 hours after in situ incubation. As the radiation dose increased, the rate of PLDR fastened and the magnitude of increased surviving fraction at saturation level by PLOR also increased. In analysis of cell survival curve fitted to the linear-quadratic model, the linear inactivation coefficient $(\alpha)$ decreased largely and reached nearly to zero but the quadratic inactivation coefficient $(\beta)$ increased minimally by increment of postirradiation in situ incubation time. So PLDR mainly affected the damage expressed as $\alpha$, In the multitarget model, significant change was not obtained in $D_0\;but\;in D_q$. Therefore, shoulder region in cell survival curve was mainly affected by PLDR and terminal slope was not influenced at all. And dose-modifying factor by PLDR was relatively higher in shoulder region, that is, in low dose area below 3 Gy.

• Proceedings of the Ginseng society Conference
• /
• 1984.09a
• /
• pp.133-140
• /
• 1984

인체가 방사선에 의해 손상을 받게 되면, 실제적으로 치료, 회복시킨 수 있는 물질은 아직 발견되지 않았다. 이에 저자는 720R의 X-선을 조사시킨 mice에 Oura 등의 방법에 따라 부분 정제한 인삼 추출물을 투여하여 X-선 손상으로부터의 회복능을 검정하였다. 주사한 인삼 추출물의 용량에 의존적으로 30일간의 생존율이 증가하였다. Saline을 주사한 대조군과 인삼 추출물을 주사한 실험군 사이의 생존율의 차이는, 동물 한 마리당 1.8mg을 투여한 실험에서 조차 통계학적으로 유의성을 보였다. (P<0.001) 550R의 X-선을 조사시킨 mice에 인삼 추출물을 투여하면 적혈구와 혈소판의 양적 회복이 촉진되었다. 또한 인삼 추출물중 열에 안정한 분획이 비장이 비대하여지는 것과 같은 부작용이 없어 방사선의 손상으로부터 보호 효과가 있음을 알았다. 이 분획은 mice뿐만 아니라, 반치사량의 X-선을 조사한 rat, guinea pig와 같은 실험동물에 있어서도 30일간의 생존율이 더 연장되므로서 현저한 효과를 보였다. 혈액상태 특히 혈소판의 양적 회복은 열에 안정한 이 분획에 의해서도 촉진되었다. 열에 안정한 분획을 투여한 mice에 있어서 X-선 조사에 의한 출혈이 방지되는데, 이를 매일 매일의 변에서 잠재혈액을 측정함으로써 정량적으로 관찰하였다. 결론적으로, 인삼 투여로 방사선에 의한 치사율이 감소되는데 이의 기전은 혈소판 생성을 촉진시키며, X-선에 의한 출혈을 감소시키기 때문이다.

• Journal of the Korean Society of Radiology
• /
• v.11 no.3
• /
• pp.147-151
• /
• 2017

Potentially lethal damage repair (PLDR) in HFL-I was investigated by delayed plating experiments. The surviving fraction data were fitted to the linear Quadratic equation ($LogSn=-n{\gamma}({\alpha}d+{\beta}d^2$) where ${\gamma}=1$ for immediate plating). And a repair factor ${\gamma}$ was developed to compare survival for immediate and delayed plating. When we only took into account the repair factor of PLDR ${\gamma}$ which was derived from the delay assay, the cell survival response th fractionated carbon ion irradiation was not fully matched. This gap suggested that consideration of another repair process is necessary. So this suggests that the various repair process plays an important role in the fractionated irradiations.

• Journal of Life Science
• /
• v.30 no.7
• /
• pp.651-659
• /
• 2020

Cardiovascular disease is one of the leading causes of death across the world, and gold-standard treatments such as percutaneous coronary intervention and artery bypass grafting have various limitations including myocardial damage and subsequent maladaptive cardiac remodeling. To overcome this, stem-cell therapies are emerging as a promising strategy for cardiovascular regeneration. Endothelial progenitor cells (EPCs) have high potential to proliferate and differentiate into endothelial cells for vascularization and tissue regeneration, and several clinical trials have explored EPC function in tissue repair in relation to clinical safety and improving cardiac function. Consequently, EPC has been suggested as a feasible stem-cell therapy. However, autologous EPC transplantation in cardiovascular disease patients is restricted by risk factors such as age, smoking status, and hypertension that lead to reduced bioactivity in the EPCs. New approaches for improving EPC function and stem-cell efficacy have therefore been suggested, including cell priming, organoid culture systems, and enhancing transplantation efficiency through 3D bioprinting methods. In this review, we provide a comprehensive understanding of EPC characteristics, therapeutic approaches, and the current state of clinical research into EPCs as stem-cell therapy for cardiovascular disease.